Search
BIO International 2025: Perspective Therapeutics CEO Thijs Spoor describes why the company prefers radiopharmaceuticals with alpha-particles, and breaks down three main programs
He describes why he likes the strong and quick elements of alpha-particles, and how Perspective's have been designed to have a short...
Jun 17, 2025
BIO International 2025: CEO Paul Hastings discusses the progress Nkarta is making on its NK cell approach to autoimmune conditions
He describes why he believes NK cells are better suited thank T-cells for autoimmune, and updates us on the company's clinical programs....
Jun 17, 2025
BIO International 2025: Germany's Aicuris, a company that focuses on helping immunocompromised patients, has breakthrough therapy designation for its HSV treatment that is in a pivotal
CEO Larry Edwards describes the unmet need in the immunocompromised space, and highlights Aicuris' commercial CMV product (PREVYMIS),...
Jun 17, 2025
BIO International 2025: UroGen CEO Liz Barrett discusses last week's approval of ZUSDURI for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer
She describes the unmet need for a new therapy in this setting, and compares and contrasts ZUSDURI to going through multiple...
Jun 16, 2025
BIO International 2025: CEO Steve Favaloro introduces us to Genezen - a best-in-class CDMO with a preclinical to commercial offering
From the floor of the BIO International Convention, he describes the services that Genezen offers, its growth, and how it can partner...
Jun 16, 2025
BIO International 2025: eGenesis CEO Mike Curtis discusses the case of the second patient who has received a transplant using the company's genetically engineered porcine kidney, and what is next
He describes the successful transplant of Tim Andrews, who threw out the first pitch at a Red Socks game last week, and discusses what is...
Jun 16, 2025
BIO International 2025: Stifel's Tim Opler comments on improvements in sentiment he is seeing for the biotech sector, and his take on hot button issues
He explains how M&A and fundraising have been improving, and he describes what types of companies have been most appealing to investors....
Jun 16, 2025
BIO International 2025: An intro to the BIO International Convention, and stopping by the Korea Pavilion
From the floor of the 2025 BIO International Convention in Boston, Brad Loncar describes what this four-day conference is all about, and...
Jun 16, 2025
BIO International 2025: Ocugen CEO Shankar Musunuri discusses the company's gene therapy platform for eye conditions - one of which is already in a pivotal, with another to start
He discusses the company's gene therapy approach to retinitis pigmentosa, Stargardt disease (which just had a pivotal cleared by FDA...
Jun 16, 2025
Welcoming Genezen to the BiotechTV family today as a new sponsor
Genezen is a best-in-class CDMO with over a decade of experience and state-of-the-art viral vector facilities. Genezen's advanced...
Jun 16, 2025
BioVenture VoiCes Episode 21: Scion Life Sciences' Aaron Kantoff
Aaron Kantoff describes the road on the public markets side that eventually led him to venture, and recalls successful investments he...
Jun 16, 2025
EHA 2025: Arcellx CEO Rami Elghandour discusses the results presented today of the iMMagine-1 Study for the company's BCMA CAR-T
He goes over the results, and compares and contrasts the therapy's profile to the primary competitor that is currently on the market,...
Jun 14, 2025
EHA 2025: The CEO of Ascentage Pharma, which had its U.S. IPO earlier this year, introduces us to the company and discusses BCR-ABL, Bcl-2, and EED targeting programs
Dajun Yang shares the history of Ascentage, talks about what makes the BCR-ABL program, which Takeda took an option on, a...
Jun 14, 2025
EHA 2025: MaaT Pharma presented an update for its microbiome based treatment for GVHD, Xervyteg, which it has now filed for approval with the EMA
CMO Gianfranco Pittari walks us through data from the pivotal ARES study that MaaT announced in January and filed with the EMA. Plus, an...
Jun 14, 2025
Microsoft's Chief Scientific Officer for Health and Life Sciences shares his take on how AI is changing healthcare today and what is possible in the future
Matthew Lungren describes his belief how AI will "save time before it saves lives," and discusses how the clinical workforce is getting...
Jun 13, 2025
EHA 2025: CEO Arthur Sands discusses Nurix Therapeutics' BTK degrader data, the development plan ahead, recent #AACR25 data regarding brain penetration, and activity in the autoimmune space
He discusses the P1 data presented at EHA for CLL and WM, which he says showed efficacy across mutations, durability, and clean safety....
Jun 13, 2025
EHA 2025: CEO Jonathan Dickinson discusses Innate Pharma's NK cell engager platform (ANKET), recent ASCO data for Lacutamab, and other program updates
He describes Innate's NK cell platform and covers programs targeting CD20, CD123, BCMA, and B7-H3. Plus Lacutamab data, updates on the...
Jun 13, 2025
CLAIRITY BREAST, an AI platform that predicts five-year breast cancer risk from routine mammograms, became the first such AI tool to receive FDA authorization for breast cancer prediction
CEO Leff Luber describes the tool, which is mean to augment a radiologist's analysis, and how its modeling algorithm takes into account...
Jun 11, 2025
Cullinan Therapeutics' CEO Nadim Ahmed covers last week's #ASCO25 data for zipalertinib in EGFRex20 insertion lung cancer, plus an in-depth conversation about bispecifics for autoimmune conditions
He highlights the zipalertinib ASCO data, which was in the relapsed setting and will be used by Cullinan's partner, Taiho, to file for...
Jun 10, 2025
Nucleate UK held its "The Forum" event in London - where it brought together the biotech community for networking, education, and to celebrate companies that have been through its Activator program
BiotechTV attended the event, and recorded comments from the Nucleate team, who describe the scale and role of Nucleate in this area. We...
Jun 9, 2025
.png){kind=logo}
